Leading US MIM producer Phillips-Medisize to be acquired by Molex LLC
September 7, 2016
Phillips-Medisize Corporation, a provider of design, development and manufacturing services for the medical industry, announced on August 17th that it had entered into a binding agreement to be acquired by Molex LLC. Phillips-Medisize is also one of North America’s largest MIM producers and a portfolio company of San Francisco based Golden Gate Capital, a US private equity investment firm with approximately $15 billion of capital under management.
Molex designs and manufactures electronic, electrical and fibreoptic systems, employing over 40,000 people in more than 40 countries. “Molex and Phillips-Medisize share a similar culture and approach to managing the business that creates strong partnerships built on quality and innovation,” said Matt Jennings, Chairman, President and CEO of Phillips-Medisize. “Molex’s global scale in electronics, coupled with Phillips-Medisize’s strength in designing and manufacturing innovative products for medical device customers, will help us become a global leader in connected health solutions.”
Molex’s global scale in electronics, coupled with Phillips-Medisize’s strength in designing and manufacturing innovative products for medical device customers, will help us become a global leader in connected health solutions.”
“Phillips-Medisize has a talented, experienced and innovative team that has strong customer relationships because of its outstanding ability to serve the unique needs of the medical solutions market,” stated Tim Ruff, Senior Vice President of Business Development and Corporate Strategy, Molex LLC. “Combined with Molex’s expertise in electronics and broad global manufacturing presence, we are confident that together we can significantly expand our medical solutions capabilities globally.”
Rajeev Amara, a Managing Director of Golden Gate Capital, stated, “In just three years of our ownership, Phillips-Medisize has executed on a transformative vision to become a global leader in the manufacturing of biologics drug delivery devices. We would like to thank all the employees for their hard work and wish them well in the future.” Terms of the transaction were not disclosed.